Logo
x

Search

Subscribe Now

Sanofi

Sanofi Publishes the P-III (XTEND-Kids) Study Data of Altuviiio to Treat Children with Severe Hemophilia A in the NEJM

Sanofi Publishes the P-III (XTEND-Kids) Study Data of Altuviiio to Treat Children with Severe Hemophilia A in the NEJM

  • July 18, 2024
PharmaShots Weekly Snapshots (July 01 – July 05, 2024)

PharmaShots Weekly Snapshots (July 01 – July 05, 2024)

  • July 5, 2024
Sanofi Reports the P-II Study Data of Frexalimab for the Treatment of Multiple Sclerosis

Sanofi Reports the P-II Study Data of Frexalimab for the Treatment of Multiple Sclerosis

  • July 1, 2024
Sanofi Reports the P-II Study Data of Riliprubart to Treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Sanofi Reports the P-II Study Data of Riliprubart to Treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  • June 26, 2024
Sanofi Highlights the P-III (IMROZ) Study Data of Sarclisa for Newly Diagnosed Transplant-Ineligible Multiple Myeloma

Sanofi Highlights the P-III (IMROZ) Study Data of Sarclisa for Newly Diagnosed Transplant-Ineligible Multiple Myeloma

  • June 4, 2024
Sanofi & Regeneron’s Dupixent Receives the CHMP’s Positive Opinion for Treating Chronic Obstructive Pulmonary Disease (COPD)

Sanofi & Regeneron’s Dupixent Receives the CHMP’s Positive Opinion for Treating Chronic Obstructive Pulmonary Disease (COPD)

  • May 31, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.